SCHEMBL3306840

SCHEMBL3306840

COC(=O)c1ccccc1Nc1c(-c2cc3nccnc3c(F)c2F)c(C)nn1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 13/20 0.54
ADORA2B P29275 2/20 0.54
ADORA2A P29274 1/20 0.54
ADORA3 P0DMS8 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
THRB P10828 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306148 0.93 ADORA1 (0.54) ADORA1ADORA2BADORA2AADORA3TDP1
SCHEMBL1818419 0.92 ADORA1 (0.61) ADORA1ADORA2BADORA2AADORA3MAPT
SCHEMBL1818975 0.90 ADORA1 (0.64) ADORA1ADORA2BADORA2AADORA3
SCHEMBL3304822 0.86 ADORA1 (0.59) ADORA1ADORA2BADORA2AADORA3KDM4E
SCHEMBL1813615 0.86 ADORA1 (0.71) ADORA1ADORA2BADORA2AADORA3TDP1
SCHEMBL1815311 0.85 ADORA1 (0.50) ADORA1ADORA2BADORA2AADORA3KMT2A
SCHEMBL3306740 0.83 ADORA1 (0.62) ADORA1ADORA2BADORA2AADORA3
SCHEMBL3306844 0.83 ADORA1 (0.53) ADORA1ADORA2BADORA2AADORA3MAPT
SCHEMBL1817422 0.83 ADORA1 (0.76) ADORA1ADORA2BADORA2AADORA3
SCHEMBL3305195 0.83 ADORA1 (0.61) ADORA1ADORA2BADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
WO-2010020363-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF CYP3A5, ABAT, TPMT ADORA1 724/4885ADORA2B 379/4885ADORA2A 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.